ClinicalTrials.gg

Program

Avapritinib

Also written as “avapritinib” and “CS3007 (BLU-285)”.

Its studies are mostly in Gastrointestinal Stromal Tumors · Mastocytosis, Systemic · Leukemia, Mast-Cell · Central Nervous System Neoplasms, led by 2 companies.

Furthest: phase 4, since Mar 29, 202110 company-led studies, 2 open or runningNext primary completion: Jun 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi92 open or runningphase 4since Mar 29, 2021Jul 23, 2015Jun 23, 2027phase 2 · NCT03731260
CStone Pharmaceuticals10 open or runningphase 2since Dec 9, 2019Dec 9, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2015First study: phase 1 study in Gastrointestinal Stromal TumorsNew to SanofiSanofi · NCT02508532 · 250 enrolled · United States, Belgium, France and more
  2. Sep 15, 2015Phase 1 study in Mastocytosis, SystemicSanofi · NCT02561988 · 86 enrolled · United States, United Kingdom
  3. Mar 7, 2018Phase 3 study in Gastrointestinal Stromal TumorsSanofi · NCT03465722 · 476 enrolled · United States, Australia, Austria and more
  4. May 3, 2018Phase 2 study in Mastocytosis, SystemicSanofi · NCT03580655 · 107 enrolled · United States, Austria, Canada and more
  5. Oct 30, 2018Phase 2 study in Mastocytosis, SystemicSanofi · NCT03731260 · 251 enrolled · United States, Belgium, Canada and more
  6. Dec 9, 2019CStone Pharmaceuticals's first study: phase 2 study in Gastrointestinal Stromal TumorsNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT04254939 · 65 enrolled · China
  7. Feb 9, 2021Phase 2 study in Central Nervous System NeoplasmsSanofi · NCT04773782 · 29 enrolled · United States, Australia, Austria and more
  8. Mar 29, 2021Phase 4 study in Gastrointestinal Stromal TumorsSanofi · NCT04825574 · 2 enrolled · France
  9. May 27, 2021Phase 1 study in Gastrointestinal Stromal TumorsSanofi · NCT04908176 · 10 enrolled · United States
  10. Dec 19, 2024Phase 4 study in Mastocytosis, SystemicSanofi · NCT06748001 · 60 planned · Belgium, Canada, France and more

Ahead

  1. Jun 23, 2027Primary completion: phase 2 study in Mastocytosis, SystemicSanofi · NCT03731260
  2. Dec 31, 2027Primary completion: phase 4 study in Mastocytosis, SystemicSanofi · NCT06748001

TargetBeta

KIT →PDGFRA →read by rule
“An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06748001Mastocytosis, Systemic · Belgium, Canada, France and more4RecruitingSanofiDec 31, 202760
NCT04908176Gastrointestinal Stromal Tumors · United States1CompletedSanofiMar 1, 202410
NCT04825574Gastrointestinal Stromal Tumors · France4CompletedSanofiNov 23, 20232
NCT04773782Central Nervous System Neoplasms · United States, Australia, Austria and more2CompletedSanofiNov 21, 202529
NCT04254939Gastrointestinal Stromal Tumors · China2CompletedCStone PharmaceuticalsApr 30, 202065
NCT03731260Mastocytosis, Systemic · United States, Belgium, Canada and more2Active, not recruitingSanofiJun 23, 2027251
NCT03580655Mastocytosis, Systemic · United States, Austria, Canada and more2CompletedSanofiDec 18, 2024107
NCT03465722Gastrointestinal Stromal Tumors · United States, Australia, Austria and more3CompletedSanofiMar 9, 2020476
NCT02561988Mastocytosis, Systemic · United States, United Kingdom1CompletedSanofiOct 5, 202286
NCT02508532Gastrointestinal Stromal Tumors · United States, Belgium, France and more1CompletedSanofiMar 6, 2020250

How it is read

Names in the registry

  • “Avapritinib”, 7 entries
  • “avapritinib”, 2 entries
  • “CS3007 (BLU-285)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.